SCHEMBL524893

SCHEMBL524893

O=C1CNc2cccnc2O1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OTUD7B Q6GQQ9 2/20 0.35
CYP1A2 P05177 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GSK3B P49841 3/20 0.33
CDK5 Q00535 2/20 0.33
CDK5R1 Q15078 2/20 0.33
KDR P35968 2/20 0.33
GSK3A P49840 1/20 0.33
CCNB2 O95067 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
CCNB3 Q8WWL7 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473898 1.00 OTUD7B (0.35) OTUD7BCYP1A2SMN1; SMN2GAANPSR1
SCHEMBL29677252 1.00 OTUD7B (0.35) OTUD7BCYP1A2SMN1; SMN2GAANPSR1
SCHEMBL9755439 0.82 OTUD7B (0.34) OTUD7BCYP1A2SMN1; SMN2GAAGSK3B
SCHEMBL6016133 0.75
SCHEMBL7339970 0.74 GAA (0.64) GAANPSR1MEN1KMT2AALOX15
SCHEMBL1256236 0.73 DYRK1A (0.36) GSK3BCDK5KDRGSK3AAKR1B1
SCHEMBL19615918 0.71
SCHEMBL323313 0.71 GAA (0.60) GAANPSR1BRPF1MEN1KMT2A
SCHEMBL29358961 0.71 GAA (0.60) GAANPSR1BRPF1MEN1KMT2A
SCHEMBL16430007 0.70 NPC1 (0.40) CYP1A2SMN1; SMN2GAANPSR1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016007736-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-01-14 WO claimed
WO-2017147505-A1 METHODS OF TREATING MUSCLE AND LIVER DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-31 WO disclosed
WO-2016007736-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-01-14 WO disclosed
EP-2858635-A1 INHIBITORS OF HIPPO-YAP SIGNALING PATHWAY The Regents of The University of California (US) 2015-04-15 EP disclosed
EP-2788336-A1 BENZOTHIAZOL- 6 -YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION Gilead Sciences, Inc. (US) 2014-10-15 EP disclosed
WO-2013188138-A1 INHIBITORS OF HIPPO-YAP SIGNALING PATHWAY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-12-19 WO disclosed
WO-2013173506-A2 METHOD OF TREATING MUSCULAR DEGRADATION RIGEL PHARMACEUTICALS, INC. (US) 2013-11-21 WO disclosed
WO-2013159064-A1 BENZOTHIAZOL- 6 -YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES, INC. (US) 2013-10-24 WO disclosed
EP-2598500-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY Rigel Pharmaceuticals, Inc. (US) 2013-06-05 EP disclosed
WO-2013052444-A1 MITIGATION OF DISEASE BY INHIBITION OF GALECTIN-12 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-04-11 WO disclosed
WO-2012015972-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS, INC. (US) 2012-02-02 WO disclosed
EP-2370415-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY Rigel Pharmaceuticals, Inc. (US) 2011-10-05 EP disclosed
WO-2010075558-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS, INC. (US) 2010-07-01 WO disclosed